A sensitive spectrofluorimetric method was developed for determination of ciprofloxacin (CPFX), levofloxacin (LEV), gatifloxacin (GAT) and moxifloxacin (MOX) in pure, commercial formulations, human urine and plasma. The method is based on charge-transfer (CT) complex with chloranilic acid. Fluorescence intensity of the complexes was measured at emission wavelength ranging from 445-492 nm with excitation wavelengths from 285-330 nm. At optimum experimental conditions, a linear calibration plot was obtained in the concentration range of 20-1000 ng·mL-1, 60-320 ng·mL-1, 20-800 ng·mL-1 and 20 -00 ng·mL-1 for CPFX, LEV, MOX and GAT, respectively with good correlation coefficient in the range of 0.9929-1.0 in methanolic medium. The limit of detection and limit of quantification were found to be 5 ng·mL-1 and 18 ng·mL-1 for CPFX, 12 ng·mL-1 and 40 ng·mL-1 for LEV, 8 ng·mL-1 and 19 ng·mL-1 for MOX, 6 ng·mL-1 and 19 ng·mL-1 for GAT, respectively. The method was found free of interferences from excipients used as additive in pharmaceutical preparations, some common cations and compounds present in urine and plasma as well as co-administered analgesic, vitamins and other drugs. The method was successfully applied for quantification of selected fluoroquinolones in commercial formulations and also in spiked human urine and plasma samples with percent recoveries of 100.0 ± 1.56 and 100.2 ± 1.29 respectively.
 R. N. Jones and L. A. Mandell, “Fluoroquinolones for the Treatment of Outpatient Community-Acquired Pneumonia,” Diagnostic Microbiology and Infectious Disease, Vol. 44, No. 1, 2002, pp. 69-76.
 H. Askal, I. Refaat, I. Darwish and M. Marzouq, “Evaluation of N-Bromosuccinimide as a New Analytical Reagent for the Spectrophotometric Determination of Fluoroquinolone Antibiotics,” Chemical and Pharmaceutical Bulletin, Vol. 55, No. 11, 2007, pp. 1551-1556.
 C. Carbon, “Comparison of Side Effects of Levofloxacin versus Other Fluoroquinolones,” Chemotherapy, Vol. 47, Suppl. 3, 2000, pp. 9-14.
 R. C. Owens, “Clinical Use of the Fluoroquinolones,” Medical Clinics of North America, Vol. 84, No. 6, 2000, pp. 1447-1469.
 P. Ihrke, M. Papich and T. Demanuelle, “The Use of Fluoroquinolones in Veterinary Dermatology,” Veterinary Dermatology, Vol. 10, No. 3, 1999, pp. 193-204.
 K. Kaur, A. Kumar, A. K. Malik, B. Singh and A. Rao, “Spectrophotometric Methods for the Determination of Fluoroquinolones: A Review,” Critical Reviews in Analytical Chemistry, Vol. 38, No. 1, 2008, pp. 2-18.
 S. Ulu, “Spectrofluorimetric Determination of Fluoroquinolones in Pharmaceutical Preparations,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy Vol. 72, No. 5, 2009, pp. 1038-1043.
 A. M. El-Brashy, M. M. El-Sayed and F. A. El-Sepai, “Spectrophotometric Determination of Some Fluoroquinolone Antibacterials by Binary Complex Formation with Xanthene Dyes,” Il Farmaco, Vol. 59, No. 10, 2004, pp. 809-817.
 M. R. Jan, J. Shah and Inyatullah, “Spectrophotometric Determination of Sparfloxacin in Pharmaceutical Formulations and Urine Samples,” Journal of Applied Spectroscopy, Vol. 77, No. 3, 2010, pp. 400-405.
 H. Salem, “Spectrofluorimetric, Atomic Absorption Spectrometric and Spectrophotometric Determination of Some Fluoroquinolones,” American Journal of Applied Sciences, Vol. 2, No. 3, 2005, pp. 719-729.
 H. Liang, M. B. Kays and K. M. Sowinski, “Separation of Levofloxacin, Ciprofloxacin, Gatifloxacin, Moxifloxacin, Trovafloxacin and Cinoxacin by High-Performance Liquid Chromatography: Application to Levofloxacin Determination in Human Plasma,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 772, No. 1, 2002, pp. 53-63.
 E. Nemutlu, K. S. Ozyüncü and M. Beksac, “Simultaneous Separation and deTermination of Seven Quinolones Using HPLC: Analysis of Levofloxacin and Moxifloxacin in Plasma and Amniotic Fluid,” Chromatographia, Vol. 66, No. 1, 2007, pp. 15-24.
 A. F. Faria, M. V. N. de Souzab and M. A. L. de Oliveira, “Validation of a Capillary Zone Electrophoresis Method for the Determination of Ciprofloxacin, Gatifloxacin, Moxifloxacin and Ofloxacin in Pharmaceutical Formulations,” Journal of the Brazilian Chemical Society, Vol. 19, No. 3, 2008, pp. 389-396.
 A. E. Radi, T. Wahdan, Z. Anwar and H. Mostafa, “Electro-Chemical Determination of Gatifloxacin, Moxifloxacin and Sparfloxacin Fluoroquinolonic Antibiotics on Glassy Carbon Electrode in Pharmaceutical Formulations,” Drug Testing and Analysis, Vol. 2, No. 8, 2010, pp. 397-400. http://dx.doi.org/10.1002/dta.143
 L. M. Du, H. Y. Yao and M. Fu, “Spectrofluorimetric Study of the Charge-Transfer Complexation of Certain Fluoroquinolones with 7,7,8,8-Tetracyanoquinodimethane,” Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, Vol. 61, No. 1-2, 2005, pp. 281-286.
 L. M. Du, Y. Q. Yang and Q. M. Wang, “Spectrofluorometric Determination of Certain Quinolone through Charge Transfer Complex Formation,” Analytica Chimica Acta, Vol. 516, No. 1-2, 2004, pp. 237-243.
 D. Liming, X. Qingqin and Y. Jianmei, Fluorescence Spectroscopy Determination of Fluoroquinolones by Charge-Transfer Reaction,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, No. 4, 2003, pp. 693-698.
 H. Salem, L. Fada and W. Khater, “Spectrofluorimetric Determination of Certain Fluoroquinolones through Charge Transfer Complex Formation,” American Journal of Pharmacology and Toxicology, Vol. 2, No. 1, 2007, pp. 18-25.
 J. Shah, M. R. Jan, Inayatullah and M. Naeem, “Micellar-Enhanced Spectrofluorometric Quantification of Moxifloxacin in Pharmaceutical Formulations, Human Urine and Plasma Samples,” African Journal of Pharmacy and Pharmacology, Vol. 5, No. 5, 2011, pp. 616-624.